Compare TILE & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | AGIO |
|---|---|---|
| Founded | 1973 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1994 | 2013 |
| Metric | TILE | AGIO |
|---|---|---|
| Price | $28.89 | $27.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $36.00 | ★ $38.88 |
| AVG Volume (30 Days) | 517.8K | ★ 709.3K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 32.43 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $1,386,854,000.00 | $43,011,000.00 |
| Revenue This Year | $6.72 | $76.75 |
| Revenue Next Year | $5.61 | $170.73 |
| P/E Ratio | $71.95 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $20.01 | $22.24 |
| 52 Week High | $35.11 | $46.00 |
| Indicator | TILE | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 44.68 |
| Support Level | $26.60 | $26.75 |
| Resistance Level | $28.89 | $29.37 |
| Average True Range (ATR) | 1.02 | 1.21 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 58.14 | 21.03 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.